|Other names||Levomeloxifene; 6720-CDRI; NNC-460020|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||457.604 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Levormeloxifene (INN; developmental code names 6720-CDRI, NNC-460020) is a selective estrogen receptor modulator (SERM) which was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed. The development was stopped because of a high incidence of gynecological side effects during clinical trials. Levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|